Switching from existing anti-VEGF agents to ranibizumab BS in age-related macular degeneration

Switching from existing anti-VEGF agents to ranibizumab BS in age-related macular degeneration - Switching from existing anti-VEGF agents to ranibizumab BS in AMD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048394

Enrollment

Registered

2022-07-18

Start date

2022-07-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with AMD who has been treated with existing anti-VEGF agents using the Treat and Extend (TAE) regimen for more than one year and who has decided to switch to ranibizumab BS at the patient's request.

Exclusion criteria

Exclusion criteria: Patients with unstable drug administration intervals with TAE regimen using existing anti-VEGF drugs, patients with other concomitant ocular diseases such as active uveitis and proliferative diabetic retinopathy, patients who have undergone previous vitrectomy or treatment with unknown details at other hospitals, and patients for whom anterior chamber fluid sampling by anterior chamber puncture is deemed unsafe.

Design outcomes

Primary

Measure	Time frame
Interval/frequency of anti-VEGF agents during the follow-up period	—

Countries

Japan

Contacts

Public ContactJun Takeuchi

Nagoya University Hospital Department of Ophthalmology

takeuchi.jun@med.nagoya-u.ac.jp052-744-2275

Outcome results